Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biovaxys Technology Corp (OP:BVAXF)

0.1980 +0.0105 (+5.60%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 35,364
Open 0.1905
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1875
Today's Range 0.1853 - 0.2000
52wk Range 0.0148 - 0.2210
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB), SpayVac-for-Wildlife Inc. Expand License Agreement
Via Investor Brand Network
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire

Performance

YTD
+324.0%
+324.0%
1 Month
-8.4%
-8.4%
3 Month
+808.3%
+808.3%
6 Month
+571.2%
+571.2%
1 Year
+258.0%
+258.0%

More News

Read More
BioVaxys Technology Corp. to Present at the Life Sciences Investor Forum September 19th 2024
From Virtual Investor Conferences
Via GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
From Virtual Investor Conferences
Via GlobeNewswire
BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine
Via FinancialNewsMedia
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
Via FinancialNewsMedia
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
Via FinancialNewsMedia
Topics Intellectual Property
BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps
Via FinancialNewsMedia
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
Via FinancialNewsMedia
Topics Death
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
Via FinancialNewsMedia
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
Via FinancialNewsMedia
Topics Intellectual Property
BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction
Via FinancialNewsMedia
Topics Economy
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
Via FinancialNewsMedia
Biotech Sector’s Response to Omicron Panic Should be Swift and Effective
Via FinancialNewsMedia
BIOVAXYS ANNOUNCES MAJOR RESEARCH COLLABORATION WITH THE OHIO STATE UNIVERSITY TO DEVELOP BROADLY REACTIVE PAN-SARBECOVIRUS VACCINE
Via FinancialNewsMedia
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
Via FinancialNewsMedia
Covid-19 Test Shortage Emphasized by New $70M Plan to Speed Up Authorizations
Via FinancialNewsMedia
Global COVID-19 Therapeutics Market Size Now Expected To Exceed $25 Billion In 2030
Via FinancialNewsMedia
Topics Death
BioVaxys announces that CoviDTH Demonstrates Safety and Tolerability in Broad Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTH
Via FinancialNewsMedia
Faster, Cheaper, More Reliable COVID-19 Tests Needed for the Unprecedented Demand Ahead
Via FinancialNewsMedia
Scientific Reports Revealing Early Promise for Universal Coronavirus Vaccine
Via FinancialNewsMedia
BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine
Via FinancialNewsMedia
Topics Intellectual Property
New Covid-19 Vaccines Continue to Be Developed by Biotech Firms Seeking to Improve the Jab
Via FinancialNewsMedia
Big Changes Coming to Covid Testing in Response to Rising Demand Under Latest Mandates
Via FinancialNewsMedia
Why Some Experts Say for an Effective COVID Vaccine, Look Beyond Antibodies to T-Cells
Via FinancialNewsMedia

Frequently Asked Questions

Is Biovaxys Technology Corp publicly traded?
Yes, Biovaxys Technology Corp is publicly traded.
What exchange does Biovaxys Technology Corp trade on?
Biovaxys Technology Corp trades on the OTC Traded
What is the ticker symbol for Biovaxys Technology Corp?
The ticker symbol for Biovaxys Technology Corp is BVAXF on the OTC Traded
What is the current price of Biovaxys Technology Corp?
The current price of Biovaxys Technology Corp is 0.1980
When was Biovaxys Technology Corp last traded?
The last trade of Biovaxys Technology Corp was at 10/24/25 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.